# FDA 483 - Syed Ali, M.D. - July 03, 2025

Source: https://www.keypedia.com/records/483/syed-ali-md/201d7b56-b1c3-4f5b-979a-bfe5cc38eed4

> FDA 483 for Syed Ali, M.D. on July 03, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Syed Ali, M.D.
- Inspection Date: 2025-07-03
- Product Type: drugs
- Office Name: Los Angeles District Office
- Summary: An FDA inspection of Syed O. Ali, M.D. in Sugar Land, TX, a clinical investigator, revealed a significant deficiency in the conduct of an investigation. The firm failed to adhere to the investigational plan, specifically by improperly randomizing subjects who did not meet screening criteria and by not completing all required screening safety labs prior to determining subject eligibility. These issues indicate a lack of proper oversight in clinical trial execution.

## Related Officers

- [Iris C. Macinnes](https://www.keypedia.com/people/iris-c-macinnes/5e8d7fef-18d5-453d-82b2-19e8e2897d26)

Company: https://www.keypedia.com/companies/syed-ali-md/2a0ed90c-3627-4c10-a8ed-2eb544bf55d7

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b